tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

CNTX Stock Latest News

Context Therapeutics Highlights T Cell Engager Advancements
Company AnnouncementsContext Therapeutics Highlights T Cell Engager Advancements
3h ago
8K
CNTX
Context Therapeutics appoints Chagin as Chief Medical Officer
PremiumThe Fly
Context Therapeutics appoints Chagin as Chief Medical Officer
4d ago
CNTX
Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
PremiumRatings
Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
25d ago
CNTX
Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
PremiumRatings
Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
26d ago
CNTX
Context Therapeutics CMO Claudio Dansky Ullmann to depart
PremiumThe Fly
Context Therapeutics CMO Claudio Dansky Ullmann to depart
28d ago
CNTX
Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
PremiumRatingsInnovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
1M ago
CNTX
Context Therapeutics presents preclinical data on CT-95
Premium
The Fly
Context Therapeutics presents preclinical data on CT-95
1M ago
CNTX
Context Therapeutics initiated with an Outperform at William Blair
Premium
The Fly
Context Therapeutics initiated with an Outperform at William Blair
1M ago
CNTX
Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion
PremiumRatings
Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion
1M ago
CNTX
Context Therapeutics Begins Phase 1 Trial for CT-95
PremiumCompany Announcements
Context Therapeutics Begins Phase 1 Trial for CT-95
2M ago
8K
CNTX
Context Therapeutics doses first patient in Phase 1 trial of CT-95
PremiumThe Fly
Context Therapeutics doses first patient in Phase 1 trial of CT-95
2M ago
CNTX
Context Therapeutics: 2024 Financial and Strategic Highlights
PremiumCompany Announcements
Context Therapeutics: 2024 Financial and Strategic Highlights
2M ago
CNTX
Buy Rating Affirmed for Context Therapeutics Amid Strategic Advancements and Strong Financial Position
PremiumRatingsBuy Rating Affirmed for Context Therapeutics Amid Strategic Advancements and Strong Financial Position
2M ago
CNTX
Strategic Advancements and Financial Health Propel Context Therapeutics to a ‘Buy’ Rating
Premium
Ratings
Strategic Advancements and Financial Health Propel Context Therapeutics to a ‘Buy’ Rating
2M ago
CNTX
Promising Clinical Trials and Strategic Pipeline Position Context Therapeutics for Success: A Buy Rating Justified
Premium
Ratings
Promising Clinical Trials and Strategic Pipeline Position Context Therapeutics for Success: A Buy Rating Justified
2M ago
CNTX
Context Therapeutics Advances CTIM-76 in Clinical Pipeline
PremiumCompany Announcements
Context Therapeutics Advances CTIM-76 in Clinical Pipeline
5M ago
8K
CNTX
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
PremiumThe Fly
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
5M ago
CNTX
Context Therapeutics Appoints Andy Pasternak as Chairman
PremiumCompany Announcements
Context Therapeutics Appoints Andy Pasternak as Chairman
5M ago
8K
CNTX
Context Therapeutics appoints PAsternak as Chairman of board of directors
PremiumThe Fly
Context Therapeutics appoints PAsternak as Chairman of board of directors
5M ago
CNTX
Context Therapeutics initiated with an Outperform at JMP Securities
PremiumThe FlyContext Therapeutics initiated with an Outperform at JMP Securities
5M ago
CNTX
Context Therapeutics Secures Funding for Cancer Therapy Pipeline
Premium
Company Announcements
Context Therapeutics Secures Funding for Cancer Therapy Pipeline
6M ago
8K
CNTX
Context Therapeutics initiated with a Buy at D. Boral Capital
Premium
The Fly
Context Therapeutics initiated with a Buy at D. Boral Capital
6M ago
CNTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >